Wall Street

5 Headwinds Facing Liquid Biopsies in Colon Cancer Screening

Published by
The Street

By Maxx Chatsko Exact Sciences, maker of Cologuard, won’t be dethroned anytime soon. There’s a fine line between innovation and technological hype, and many investors aren’t adept at identifying the difference. Successful growth investing relies on identifying innovations that can succeed in the market. That means addressing the pain points of customers, navigating competitive landscapes, and understanding the nuances of commercial markets. The dustbin of history is filled with best-in-class technologies that failed to become economically viable. The $18 billion market for colon-cancer screeni…

Read More

Share this Story
Load More Related Articles
Load More In Wall Street